Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis

Lessons were learned with trans women who participated (as volunteers and investigators) in trials of HIV pre-exposure prophylaxis (PrEP). Trans women are not men. Compared with men who have sex with men, trans women trial participants were more likely to be involved with transactional sex, had more...

Full description

Saved in:
Bibliographic Details
Main Authors: Robert M. Grant, Jae M. Sevelius, Juan V. Guanira, Jana Villayzan Aguilar, Suwat Chariyalertsak, Madeline B. Deutsch
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016714552&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56095
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-56095
record_format dspace
spelling th-cmuir.6653943832-560952018-09-05T03:08:51Z Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis Robert M. Grant Jae M. Sevelius Juan V. Guanira Jana Villayzan Aguilar Suwat Chariyalertsak Madeline B. Deutsch Medicine Lessons were learned with trans women who participated (as volunteers and investigators) in trials of HIV pre-exposure prophylaxis (PrEP). Trans women are not men. Compared with men who have sex with men, trans women trial participants were more likely to be involved with transactional sex, had more sexual partners, and were less likely to have PrEP medications detected in blood. Trans women define themselves differently in different cultures. One best practice is to ask at least 2 gender questions: sex assigned at birth and current gender. More information is needed to fully situate PrEP efficacy for trans women, including analysis of drug-drug interactions between PrEP medications and feminizing hormones and PrEP drug penetration into neovaginal tissues. Including trans women in studies is helpful only if their participation is specifically reported, as could occur in a table of baseline characteristics of the enrolled cohort. Gender-affirming care is important to foster appropriate uptake and use of PrEP. Such care includes use of preferred pronouns and names, safety to use the bathroom of choice, and access to gender-affirming hormone therapy and surgery. The consistent finding that PrEP works when taken across diverse populations having diverse practices related to gender, sexual intercourse, and hormone use provides a basis for offering PrEP to people at substantial risk of acquiring HIV although some subgroups may not have been fully represented in trials. Nonetheless, specific PrEP implementation science for trans women (and men) is essential to develop best practices for PrEP delivery and use. 2018-09-05T03:08:51Z 2018-09-05T03:08:51Z 2016-08-15 Journal 19447884 2-s2.0-85016714552 10.1097/QAI.0000000000001090 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016714552&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56095
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
Robert M. Grant
Jae M. Sevelius
Juan V. Guanira
Jana Villayzan Aguilar
Suwat Chariyalertsak
Madeline B. Deutsch
Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis
description Lessons were learned with trans women who participated (as volunteers and investigators) in trials of HIV pre-exposure prophylaxis (PrEP). Trans women are not men. Compared with men who have sex with men, trans women trial participants were more likely to be involved with transactional sex, had more sexual partners, and were less likely to have PrEP medications detected in blood. Trans women define themselves differently in different cultures. One best practice is to ask at least 2 gender questions: sex assigned at birth and current gender. More information is needed to fully situate PrEP efficacy for trans women, including analysis of drug-drug interactions between PrEP medications and feminizing hormones and PrEP drug penetration into neovaginal tissues. Including trans women in studies is helpful only if their participation is specifically reported, as could occur in a table of baseline characteristics of the enrolled cohort. Gender-affirming care is important to foster appropriate uptake and use of PrEP. Such care includes use of preferred pronouns and names, safety to use the bathroom of choice, and access to gender-affirming hormone therapy and surgery. The consistent finding that PrEP works when taken across diverse populations having diverse practices related to gender, sexual intercourse, and hormone use provides a basis for offering PrEP to people at substantial risk of acquiring HIV although some subgroups may not have been fully represented in trials. Nonetheless, specific PrEP implementation science for trans women (and men) is essential to develop best practices for PrEP delivery and use.
format Journal
author Robert M. Grant
Jae M. Sevelius
Juan V. Guanira
Jana Villayzan Aguilar
Suwat Chariyalertsak
Madeline B. Deutsch
author_facet Robert M. Grant
Jae M. Sevelius
Juan V. Guanira
Jana Villayzan Aguilar
Suwat Chariyalertsak
Madeline B. Deutsch
author_sort Robert M. Grant
title Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis
title_short Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis
title_full Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis
title_fullStr Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis
title_full_unstemmed Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis
title_sort transgender women in clinical trials of pre-exposure prophylaxis
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85016714552&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56095
_version_ 1681424628025655296